Select semaglutide: the cardiovascular trial and what the evidence shows

What was the SELECT trial, and why does it matter for semaglutide?

SELECT stands for Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity. It was a randomised, double-blind, placebo-controlled trial that followed 17,604 adults for an average of around four years. Every participant had pre-existing cardiovascular disease (a previous heart attack, stroke, or peripheral arterial disease) and a BMI of at least 27, but crucially none had type 2 diabetes at the start.

The primary outcome was what researchers call MACE: major adverse cardiovascular events, specifically cardiovascular death, non-fatal heart attack, and non-fatal stroke. Semaglutide 2.4 mg weekly reduced that combined risk by 20% compared with placebo. You can read more about the specific percentage reduction on our SELECT MACE reduction page.

Why does this matter? Before SELECT, the case for GLP-1 medicines in people without diabetes rested mainly on weight-loss data. SELECT added a different dimension: evidence that the medicine itself (not just the weight lost) may contribute to cardiovascular protection. Researchers are still working out exactly how much of the benefit comes from weight reduction versus direct vascular effects of semaglutide, and that question is not yet fully settled.

The full SELECT study design and results are detailed on our SELECT study overview page.

Does the SELECT finding change who semaglutide is licensed for in the UK?

Yes, though the detail matters here, because there is a common misconception that SELECT simply expanded Wegovy's weight-loss licence. It did not work quite like that.

In the UK, the MHRA authorised semaglutide (Wegovy) for an additional indication: reducing the risk of serious cardiovascular events in adults who have established cardiovascular disease and a BMI of 30 or above, or 27 or above where a weight-related condition is present. This sits alongside the existing weight-management licence rather than replacing or broadening it. The two indications have overlapping but not identical criteria, and a prescriber will assess which applies to your situation.

For context, NICE's appraisal of semaglutide for weight management (TA875) covers the weight-loss indication; the cardiovascular indication follows a separate regulatory path. Both licences are held by the same medicine (Wegovy 2.4 mg) but they serve different clinical purposes.

If you are looking at the broader picture of what semaglutide treats, our semaglutide overview page covers all current UK-licensed indications in one place.

What side effects and practical points should someone considering semaglutide know?

Whether the reason for considering semaglutide is weight management or cardiovascular risk reduction, the medicine is the same and the side-effect profile is consistent across both indications. Gastrointestinal effects (nausea, loose stools, constipation, reflux, and reduced appetite) are the most commonly reported, particularly in the early weeks and after dose increases. Most people find these settle as the body adjusts.

Less common but serious effects include acute pancreatitis. In January 2026, the MHRA issued a Drug Safety Update reminding prescribers and patients that severe or persistent stomach pain, especially if it spreads to the back, warrants prompt medical attention. Any suspected side effects can be reported at the MHRA's Yellow Card scheme.

Semaglutide is not recommended during pregnancy, while breastfeeding, or when trying to conceive, and it is not licensed for use in people under 18. A prescriber will ask about these factors as part of a full clinical assessment before any prescription is issued.

The NHS provides a full patient-level medicines guide at nhs.uk/medicines/semaglutide, which is worth reading alongside any consultation.

What is the difference between Wegovy and Ozempic for this indication?

Both Wegovy and Ozempic contain semaglutide, and this confuses a lot of people. Ozempic is licensed in the UK for type 2 diabetes; it is not licensed for weight management or for the cardiovascular indication that SELECT established. Wegovy at the 2.4 mg dose is the product that holds both the weight-management and cardiovascular licences.

Separately, the SELECT trial's cardiovascular findings also informed regulatory discussions in the EU and US, but UK readers should focus on MHRA-authorised indications rather than approvals in other jurisdictions. Semaglutide also received conditional UK approval in July 2026 for a form of fatty liver disease (MASH), you can read about that on our semaglutide and MASH page.

If you are thinking about whether Wegovy might be right for you, our Wegovy treatment page covers eligibility and the private consultation route in full. For a broader look at weight-loss options, our weight-loss treatments overview is a good starting point. And if cost is on your mind, our Wegovy cost page explains what a legitimate private price actually includes. The right first step for most people is simply a conversation, check your eligibility with our prescribers.